The US Food and Drug Administration has approved the second CAR T-cell therapy, indicated for certain types of non-Hodgkin lymphoma. READ MORE

B-Cell Malignancies

A recent study showed improved long-term survival outcomes and QoL for patients with a B-cell malignancy receiving TKI therapy.

READ MORE

An analysis of over 39,000 patients with a certain B-cell malignancy showed improved survival outcomes after radiation therapy.

READ MORE

The high economic burden of B-cell malignancies on US commercial insurers may impact future reimbursement decisions.

READ MORE

Although some patients with DLBCL may be cured of their disease, risk of non-cancer causes of death is elevated in comparison with the general population.

READ MORE

CAR-T

The ICER has released a scoping document that will compare the clinical effectiveness and value of multiple CAR-T cell treatments under review by the FDA.

READ MORE

A recent study reported an ORR of 71% in patients with CLL treated with anti-CD19 CAR-T cell therapy after prior treatment failure.

READ MORE

The oncology nurses’ responsibility in monitoring and recognizing symptoms of CAR T-cell toxicities is especially important.

READ MORE

CD19-specific CAR T-cell therapy is more likely to be effective when given immediately after front-line therapy in patients with B-cell ALL. 

READ MORE

News

The US Food and Drug Administration has approved the second CAR T-cell therapy, indicated for certain types of non-Hodgkin lymphoma.

READ MORE

Current value frameworks issued by leading medical societies may not be easily generalizable to the treatment of hematologic malignancies.

READ MORE

Research in Review

The addition of a novel monoclonal antibody to ibrutinib significantly improves survival outcomes for patients with previously treated high-risk chronic lymphocytic leukemia.

READ MORE

An intravenous consolidation regimen developed for patients with chronic lymphocytic leukemia (CLL) was found to be safe and effective, according to a report in the European Journal of Hematology (2017;98[3]:254-262).

READ MORE

Mutations in the BTK and PLCG2 genes have the potential to be used as a biomarker for relapse of chronic lymphocytic leukemia after treatment with ibrutinib.

READ MORE

Genomic profiling should be applied to patients with histiocytic disorders at diagnosis in order to guide targeted therapy.

READ MORE